drugset / Trial / NCT00069901

Phase II CT-2103/Carboplatin in Ovarian Cancer

NCT00069901

Phase 2 Completed 82 enrolled CTI BioPharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.

Timeline

Start
2003-02
Primary completion
2005-11
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject paclitaxel poliglumex Other / unclassified

Indications